x min read

Morning Alert: Alibaba Group Holding Ltd (NYSE:BABA), Nektar Therapeutics (NASDAQ:NKTR), Biodel Inc. (NASDAQ:BIOD), Merck & Co. Inc. (NYSE:MRK, Anchor Bancorp (NASDAQ:ANCB)

Morning Alert: Alibaba Group Holding Ltd (NYSE:BABA), Nektar Therapeutics (NASDAQ:NKTR), Biodel Inc. (NASDAQ:BIOD), Merck & Co. Inc. (NYSE:MRK, Anchor Bancorp (NASDAQ:ANCB)
Written by
Charles Donlon
Published on
November 10, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Ma Says Alibaba Group Holding Ltd (NYSE:BABA) Shareholders Should Feel Love, Not No. 3. Alibaba Group Holding Ltd (NYSE:BABA) belongs to Services sector. Its net profit margin is 56.00% and weekly performance is 16.19%. On last trading day company shares ended up $114.56. Alibaba Group Holding Ltd (NYSE:BABA) distance from 50-day simple moving average (SMA50) is 24.01%. On Nov. 6, Nektar Therapeutics (NASDAQ:NKTR) reported its financial results for the third quarter ended September 30, 2014. Cash and investments in marketable securities at September 30, 2014 were $261.6 million as compared to $301.4 million at June 30, 2014. Nektar Therapeutics (NASDAQ:NKTR) shares fell -1.55% in last trading session and ended the day at $13.35. NKTR Gross Margin is 75.10% and its return on assets is -32.10%. Nektar Therapeutics (NASDAQ:NKTR) quarterly performance is 2.93%. Zacks upgraded shares of Biodel (NASDAQ:BIOD) from a neutral rating to an outperform rating in a research note released on Friday morning. They currently have $1.60 target price on the stock. On 07 November, Biodel Inc. (NASDAQ:BIOD) shares moved up 0.65% and was closed at $1.54. BIOD EPS growth in last 5 year was 8.60%. Biodel Inc. (NASDAQ:BIOD) year to date (YTD) performance is -32.46%. Merck & Co. Inc. (NYSE:MRK), announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide or NS5B inhibitor for the treatment of chronic hepatitis C virus or HCV infection. Merck & Co. Inc. (NYSE:MRK) belongs to Healthcare sector. Its net profit margin is 12.50% and weekly performance is 2.42%. On last trading day company shares ended up $59.34. Merck & Co. Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 1.37%.On Oct. 27, Anchor Bancorp (NASDAQ:ANCB) reported first quarter earnings for the fiscal year ending June 30, 2015. For the quarter ended September 30, 2014, the Company reported net income of $113,000 or $0.05 per diluted share, compared to net loss of $12,000 or $0.00 per diluted share for the same period last year. Anchor Bancorp (NASDAQ:ANCB) shares remains unchanged in last trading session and ended the day at $20.15. ANCB return on assets is 0.10%. Anchor Bancorp (NASDAQ:ANCB) quarterly performance is 5.39%.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.

Recommended for You